Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INDP014
- Development stage
- Preclinical
- Lead developer
- Indaptus Therapeutics
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
INDP014 is a chemically and genetically modified platform strain of gram-negative bacteria developed by Indaptus Therapeutics for the treatment of infectious diseases. It is part of a novel immunotherapy approach that utilizes attenuated and killed, non-pathogenic gram-negative bacteria with engineered levels of lipopolysaccharide (LPS) to safely activate both innate and adaptive immune pathways. The drug is designed to deliver a multi-targeted package of bacterial pathogen-associated molecular patterns (PAMPs), which are recognized by receptors such as Toll-like receptor 4 (TLR4), NOD, STING, and RIG-I on immune cells. This activation aims to induce broad anti-viral or anti-tumor responses without relying on targeting specific antigens. INDP014 is currently in preclinical development for infectious diseases[1][5][8][9].
- Other names
- INDP-014INDP014INDP 014
02
Targets
NLRP6 inflammasomeDDX58 (Retinoic acid-inducible gene I protein)STING (Stimulator of interferon genes protein)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on INDP014.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INDP014.